KRAS is a member of the murine sarcoma virus oncogene-RAS gene family. It plays an important
role in the prevention, diagnosis and treatment of tumors during tumor cell growth and angiogenesis.
KRAS is the most commonly mutated oncogene in human cancers, such as pancreatic cancers,
colon cancers, and lung cancers. Detection of KRAS gene mutation is an important indicator for tracking
the status of oncogenes, highlighting the developmental prognosis of various cancers, and the efficacy
of radiotherapy and chemotherapy. However, the efficacy of different patients in clinical treatment
is not the same. Since RNA interference (RNAi) technologies can specifically eliminate the expression
of specific genes, these technologies have been widely used in the field of gene therapy for exploring
gene function, infectious diseases and malignant tumors. RNAi refers to the phenomenon of highly specific
degradation of homologous mRNA induced by double-stranded RNA (dsRNA), which is highly
conserved during evolution. There are three classical RNAi technologies, including siRNA, shRNA and
CRISPR-Cas9 system, and a novel synthetic lethal interaction that selectively targets KRAS mutant cancers.
Therefore, the implementation of individualized targeted drug therapy has become the best choice
for doctors and patients. Thus, this review focuses on the current status, future perspective and associated
challenges in silencing of KRAS with RNAi technology.